Atorvastatin市场：按适应症分类 - 2025-2030 年全球预测

2023年Atorvastatin市场估值为12.6亿美元，预计2024年将达到13.2亿美元，复合年增长率为5.17%，预计2030年将达到18亿美元。

Atorvastatin是一种广泛用于控制胆固醇水平和预防心血管疾病的他汀类药物，在药物製造、医疗和患者照护领域拥有全球市场。对Atorvastatin的需求源于其已被证明可有效降低低密度脂蛋白 (LDL) 胆固醇并降低心臟病发作和中风相关的风险。其用途不仅限于治疗高胆固醇症，也扩及预防混合型血脂异常和高危险群。最终用途主要包括医院、诊所和门诊诊所，随着患者转向独立的慢性病管理，家庭护理的趋势日益增长。影响该市场的主要成长要素包括全球心血管疾病盛行率的增加、人口老化以及对预防性医疗保健的日益关注。学名药的进入和消费者健康意识的提高带来了潜在的商机。公司可以透过强调可负担性、宣传Atorvastatin适应症的更广泛益处以及扩大其在医疗保健可及性不断改善的新兴市场的影响力来利用这些优势。然而，市场成长受到诸如严格的监管核准流程、导致患者违规的副作用以及来自品牌药和学名药的竞争等挑战的阻碍。创新领域包括开发提高患者依从性的联合治疗、先进的药物传输系统以及整合远端医疗平台和药物管理的数位健康解决方案。探索针对基因谱量身定制的个人化医疗方法也可能提供重要的业务成长途径。在持续的产品开发和医疗进步的推动下，Atorvastatin市场的竞争非常激烈，因此为了保持竞争力，公司必须保持敏捷并采用技术主导的解决方案，而建立策略伙伴关係至关重要。

市场动态：揭示快速发展的Atorvastatin市场的关键市场洞察

Atorvastatin市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

• 市场驱动因素
  • 全球心血管疾病盛行率不断上升
  • 医改推广预防医学
• 市场限制因素
  • 产品召回及其对品牌声誉的影响
• 市场机会
  • 政府和监管机构对心血管研究的支持
  • Atorvastatin有效治疗策略伙伴关係
• 市场问题
  • 他汀类替代药物的可用性

波特五力：驾驭Atorvastatin市场的策略工具

波特的五力框架是了解Atorvastatin市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解Atorvastatin市场的外部影响

外部宏观环境因素在塑造Atorvastatin市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解Atorvastatin市场的竞争格局

对Atorvastatin市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：Atorvastatin市场供应商的绩效评估

FPNV定位矩阵是评估Atorvastatin市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：规划Atorvastatin市场的成功之路

对于旨在加强其全球市场影响力的公司来说，Atorvastatin市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

• 市场动态
  • 促进因素
    • 全球心血管疾病盛行率不断上升
    • 医改推广预防医学
  • 抑制因素
    • 产品召回及其对品牌声誉的影响
  • 机会
    • 政府和监管机构对心血管研究的支持
    • 有效Atorvastatin治疗方法的策略合作
  • 任务
    • 他汀类替代药物的可用性
• 市场区隔分析
  • 适应症：由于饮食习惯、遗传和其他健康状况导致高高胆固醇症盛行率增加
• 波特五力分析
• PESTEL分析
  • 政治
  • 经济
  • 社会
  • 科技
  • 法律
  • 环境

第六章Atorvastatin市场：依适应症分类

• 介绍
• 血脂异常症
• 高胆固醇症
• 高三酸甘油脂血症

第七章 美洲Atorvastatin市场

• 介绍
• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第八章亚太阿托Atorvastatin市场

• 介绍
• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第九章欧洲、中东和非洲Atorvastatin市场

• 介绍
• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第10章竞争格局

• 2023 年市场占有率分析
• FPNV 定位矩阵，2023
• 竞争情境分析
  • FDA核准扩大 Esperion 心血管药物 Nexletor 和 Nexlisette 的使用
  • 欧洲健康委员会重新核准降胆固醇药物
  • NHLBI 向德州心臟研究所津贴114 万美元，用于创新心血管疾病治疗
• 战略分析和建议

公司名单

• Accord Healthcare, Inc.
• AdvaCare Pharma USA
• Anant Pharmaceuticals Pvt. Ltd.
• Apotex Inc.
• Centrient Pharmaceuticals
• Cerata Pharmaceuticals LLP
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Fengchen Group Co.,Ltd
• Hangzhou Jeci Biochem Technology Co.,Ltd.
• Hunan Huateng Pharmaceutical Co., Ltd
• Lupin Limited
• Manus Aktteva Biopharma LLP
• Merck KGaA
• Morepen Laboratories Limited
• Novartis AG
• Pfizer Inc.
• Ranbaxy Laboratories Ltd. by Sun Pharmaceutical Industries Ltd.
• SAIN Medicaments Pvt. Ltd.
• Taj Pharmaceuticals Limited
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• Torrent Pharmaceuticals Ltd.
• Viatris Inc.
• Zydus Lifesciences Limited

The Atorvastatin Market was valued at USD 1.26 billion in 2023, expected to reach USD 1.32 billion in 2024, and is projected to grow at a CAGR of 5.17%, to USD 1.80 billion by 2030.

Atorvastatin, a widely prescribed statin used for managing cholesterol levels and preventing cardiovascular disease, has a global market scope that extends across pharmaceutical manufacturing, healthcare, and patient care sectors. The necessity of atorvastatin arises from its proven efficacy in reducing low-density lipoprotein (LDL) cholesterol and thereby mitigating risks associated with heart attacks and strokes. Its application is not limited to therapy for hypercholesterolemia but also extends to cases of mixed dyslipidemia and prevention for at-risk populations. The end-use scope primarily includes hospitals, clinics, and outpatient services, with a growing trend in home-care settings as patients increasingly manage chronic conditions independently. Key growth factors influencing this market include the increasing prevalence of cardiovascular diseases globally, aging populations, and the rising focus on preventive healthcare. The entry of generic versions and the increasing health awareness among consumers present potential opportunities. Companies can capitalize on these by emphasizing affordability, promoting atorvastatin's extensive benefits, and expanding presence in emerging markets where healthcare access is improving. However, market growth is hampered by challenges such as stringent regulatory approval processes, side effect profiles leading to patient non-compliance, and competition from both branded drugs and generics. Innovation areas include the development of combination therapies that enhance patient adherence, advanced drug delivery systems, and digital health solutions that integrate medication management with telemedicine platforms. Research into personalized medicine approaches tailored to genetic profiles could also offer significant business growth avenues. The nature of the atorvastatin market is highly competitive, driven by continuous product development and healthcare advancements, making it crucial for businesses to stay agile, adopting tech-driven solutions and forging strategic partnerships to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Atorvastatin Market

The Atorvastatin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing global prevalence of cardiovascular diseases
  • Healthcare reforms promoting preventive care
• Market Restraints
  • Product recalls and impact on brand reputation
• Market Opportunities
  • Government and regulatory support for cardiovascular research
  • Strategic collaboration for effective atorvastatin based therapeutics
• Market Challenges
  • Availability of alternative statin drugs

Porter's Five Forces: A Strategic Tool for Navigating the Atorvastatin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Atorvastatin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Atorvastatin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Atorvastatin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Atorvastatin Market

A detailed market share analysis in the Atorvastatin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Atorvastatin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Atorvastatin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Atorvastatin Market

A strategic analysis of the Atorvastatin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Atorvastatin Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Inc., AdvaCare Pharma USA, Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., Centrient Pharmaceuticals, Cerata Pharmaceuticals LLP, Cipla Limited, Dr. Reddy's Laboratories Ltd., Fengchen Group Co.,Ltd, Hangzhou Jeci Biochem Technology Co.,Ltd., Hunan Huateng Pharmaceutical Co., Ltd, Lupin Limited, Manus Aktteva Biopharma LLP, Merck KGaA, Morepen Laboratories Limited, Novartis AG, Pfizer Inc., Ranbaxy Laboratories Ltd. by Sun Pharmaceutical Industries Ltd., SAIN Medicaments Pvt. Ltd., Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Atorvastatin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indications, market is studied across Dyslipidemia, Hypercholesterolemia, and Hypertriglyceridemia.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing global prevalence of cardiovascular diseases
    • 5.1.1.2. Healthcare reforms promoting preventive care
  • 5.1.2. Restraints
    • 5.1.2.1. Product recalls and impact on brand reputation
  • 5.1.3. Opportunities
    • 5.1.3.1. Government and regulatory support for cardiovascular research
    • 5.1.3.2. Strategic collaboration for effective atorvastatin based therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of alternative statin drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Indication: Increasing prevalence hypercholesterolemia of owing to dietary habits, genetics, or other health conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Atorvastatin Market, by Indications

• 6.1. Introduction
• 6.2. Dyslipidemia
• 6.3. Hypercholesterolemia
• 6.4. Hypertriglyceridemia

7. Americas Atorvastatin Market

• 7.1. Introduction
• 7.2. Argentina
• 7.3. Brazil
• 7.4. Canada
• 7.5. Mexico
• 7.6. United States

8. Asia-Pacific Atorvastatin Market

• 8.1. Introduction
• 8.2. Australia
• 8.3. China
• 8.4. India
• 8.5. Indonesia
• 8.6. Japan
• 8.7. Malaysia
• 8.8. Philippines
• 8.9. Singapore
• 8.10. South Korea
• 8.11. Taiwan
• 8.12. Thailand
• 8.13. Vietnam

9. Europe, Middle East & Africa Atorvastatin Market

• 9.1. Introduction
• 9.2. Denmark
• 9.3. Egypt
• 9.4. Finland
• 9.5. France
• 9.6. Germany
• 9.7. Israel
• 9.8. Italy
• 9.9. Netherlands
• 9.10. Nigeria
• 9.11. Norway
• 9.12. Poland
• 9.13. Qatar
• 9.14. Russia
• 9.15. Saudi Arabia
• 9.16. South Africa
• 9.17. Spain
• 9.18. Sweden
• 9.19. Switzerland
• 9.20. Turkey
• 9.21. United Arab Emirates
• 9.22. United Kingdom

10. Competitive Landscape

• 10.1. Market Share Analysis, 2023
• 10.2. FPNV Positioning Matrix, 2023
• 10.3. Competitive Scenario Analysis
  • 10.3.1. FDA Approves Expanded Use of Esperion's Cardiovascular Drugs Nexletol and Nexlizet
  • 10.3.2. Updated Approval for Cholesterol-Reducing Medications by European Health Committee
  • 10.3.3. Innovative Cardiovascular Disease Treatment on the Horizon with USD 1.14 Million NHLBI Grant to Texas Heart Institute
• 10.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Accord Healthcare, Inc.
• 2. AdvaCare Pharma USA
• 3. Anant Pharmaceuticals Pvt. Ltd.
• 4. Apotex Inc.
• 5. Centrient Pharmaceuticals
• 6. Cerata Pharmaceuticals LLP
• 7. Cipla Limited
• 8. Dr. Reddy's Laboratories Ltd.
• 9. Fengchen Group Co.,Ltd
• 10. Hangzhou Jeci Biochem Technology Co.,Ltd.
• 11. Hunan Huateng Pharmaceutical Co., Ltd
• 12. Lupin Limited
• 13. Manus Aktteva Biopharma LLP
• 14. Merck KGaA
• 15. Morepen Laboratories Limited
• 16. Novartis AG
• 17. Pfizer Inc.
• 18. Ranbaxy Laboratories Ltd. by Sun Pharmaceutical Industries Ltd.
• 19. SAIN Medicaments Pvt. Ltd.
• 20. Taj Pharmaceuticals Limited
• 21. Teva Pharmaceutical Industries Ltd.
• 22. Thermo Fisher Scientific Inc.
• 23. Torrent Pharmaceuticals Ltd.
• 24. Viatris Inc.
• 25. Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. ATORVASTATIN MARKET RESEARCH PROCESS
• FIGURE 2. ATORVASTATIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ATORVASTATIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ATORVASTATIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. AMERICAS ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 9. AMERICAS ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. UNITED STATES ATORVASTATIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 11. UNITED STATES ATORVASTATIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. ASIA-PACIFIC ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA ATORVASTATIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ATORVASTATIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 17. ATORVASTATIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ATORVASTATIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ATORVASTATIN MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ATORVASTATIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ATORVASTATIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ATORVASTATIN MARKET DYNAMICS
• TABLE 7. GLOBAL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ATORVASTATIN MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ATORVASTATIN MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ATORVASTATIN MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. AMERICAS ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 12. AMERICAS ATORVASTATIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 13. ARGENTINA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 14. BRAZIL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 15. CANADA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 16. MEXICO ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 17. UNITED STATES ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 18. UNITED STATES ATORVASTATIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 19. ASIA-PACIFIC ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 20. ASIA-PACIFIC ATORVASTATIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. AUSTRALIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 22. CHINA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 23. INDIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 24. INDONESIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 25. JAPAN ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 26. MALAYSIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 27. PHILIPPINES ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 28. SINGAPORE ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 29. SOUTH KOREA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 30. TAIWAN ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 31. THAILAND ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 32. VIETNAM ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 33. EUROPE, MIDDLE EAST & AFRICA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 34. EUROPE, MIDDLE EAST & AFRICA ATORVASTATIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. DENMARK ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 36. EGYPT ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 37. FINLAND ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 38. FRANCE ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 39. GERMANY ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 40. ISRAEL ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 41. ITALY ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 42. NETHERLANDS ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 43. NIGERIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 44. NORWAY ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 45. POLAND ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 46. QATAR ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 47. RUSSIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 48. SAUDI ARABIA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH AFRICA ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 50. SPAIN ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 51. SWEDEN ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 52. SWITZERLAND ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 53. TURKEY ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED ARAB EMIRATES ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED KINGDOM ATORVASTATIN MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 56. ATORVASTATIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 57. ATORVASTATIN MARKET, FPNV POSITIONING MATRIX, 2023